Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GL-ONC1 in advanced solid organ cancers
NCT02714374Phase 1Terminated
- Sponsor
- Andrew Lowy
- Start
- Mar 2016
- Primary completion
- Aug 2019
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of olvimulogene nanivacirepvec in solid organ cancer, sponsored by Andrew Lowy. Primary endpoint: Number of participants with treatment-related adverse events at 2.5 years. Started Mar 2016; status: terminated.
02
Drugs
olvimulogene nanivacirepvec
03
Conditions
solid organ cancer
Beyond the preview
Go deeper on NCT02714374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02714374.